Most of ENTA's current EV derives from the Mavyret royalty stream, which is running at $200M per year (pre-tax). I.e. investors are not paying so much for the NASH/PBC, RSV, and HBV programs.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”